- Ocular Therapeutix (NASDAQ:OCUL) announces that its application for a permanent Category I CPT reimburse code for the administration of drug-eluting intracanalicular inserts, including Dextenza (dexamethasone ophthalmic insert) 0.4 mg, has been accepted by the American Medical Association CPT Editorial Panel.
- The new code goes into effect on January 1, 2022.
- https://seekingalpha.com/news/3631059-ocular-nabs-permanent-u-s-reimbursement-code-for-dextenza
Wednesday, November 4, 2020
Ocular up on permanent U.S. reimbursement code for Dextenza
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.